Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413254 | 0.87 | LMNA (0.81) | LMNAALOX15PLA2G4BPTPN7PPARA | |
| SCHEMBL19359675 | 0.86 | LMNA (0.60) | LMNAALOX15PLA2G4BPTPN7PPARA | |
| SCHEMBL6170041 | 0.85 | LMNA (0.54) | LMNACYP3A4ACHE | |
| SCHEMBL9787099 | 0.84 | MAPT (0.58) | LMNACYP3A4MAPK1 | |
| SCHEMBL17028900 | 0.83 | LMNA (0.76) | LMNACYP3A4ACHEHTT | |
| SCHEMBL249305 | 0.83 | LMNA (0.76) | LMNACYP3A4ACHEHTT | |
| SCHEMBL7872215 | 0.83 | LMNA (0.70) | LMNAALOX15PLA2G4BPTPN7PPARA | |
| SCHEMBL30785439 | 0.82 | LMNA (1.00) | LMNAALOX15PLA2G4BPTPN7PPARA | |
| SCHEMBL6653396 | 0.82 | LMNA (0.59) | LMNAALOX15CYP3A4ACHEMAPK1 | |
| SCHEMBL15063356 | 0.82 | LMNA (0.74) | LMNAALOX15CYP3A4PLA2G4BPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-5262540-A | FOR INHIBITION OF BLOOD PLATELET AGGREGATION IN MAMMALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0434034-A1 | Oxazole derivatives | Bristol-Myers Squibb Company (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | LMNA 4783/4885ALOX15 2776/4885CYP3A4 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.